Background {#Sec1}
==========

Cancer is principally caused by changes in three types of genes i.e. oncogenes, tumor suppressor genes and DNA stability genes; common environmental factors contributing to these changes could be smoking, oncogenic viruses, occupational and environmental carcinogens and predisposing genetic polymorphisms \[[@CR1],[@CR2]\]. Massive research efforts are ongoing to find treatments for cancer, still an unresolved problem and of course a heavy burden on health care. Targeting specific pathways and modulating the immune system are key strategies to control cancer progression and increase effectiveness of treatment \[[@CR3]\].

EGFR, important growth factor receptor implicated in many cancers, is one of the targets for chemotherapy. EGFR belongs to ErbB family of tyrosine kinase receptors \[[@CR4]\]. In tumors these receptors are activated by increased expression or structural rearrangement of receptor gene, mutation in ligand binding or tyrosine kinase domain or by the production of autocrine and paracrine ligands. On activation, EGFR dimerizes and triggers Ras-RAF-MEK-ERK-MAPK, JAK-STAT and other signaling cascades \[[@CR4],[@CR5]\]. These pathways activate transcription factors, ultimately resulting in activation of cellular processes including proliferation, carbohydrate utilization, protein synthesis, angiogenesis, cell growth and cell survival \[[@CR4],[@CR6]\]. In cancer cells, EGFR activation is important in maintaining the metabolic homeostasis and stimulates proliferation, invasion, angiogenesis, survival, decreased apoptosis, migration, differentiation and adhesion. Because of its central signaling position, EGFR is targeted in number of malignancies e.g. lung, colorectal, pancreatic, head and neck cancers, glioblastomas etc. \[[@CR7]\].

To treat malignancies, EGFR activity is targeted with reversible, irreversible or antibody inhibitors and their combinations. Reversible inhibitors, e.g., Gefitinib and Erlotinib, compete for the intracellular ATP binding site of the kinase; the irreversible inhibitors, e.g., PF299804 and WZ4002, block the ATP binding site by covalent interaction with Cys773 in EGFR \[[@CR8]\]. Antibody inhibitors block the extracellular ligand binding domain of EGFR thereby preventing ligand binding and receptor dimerization. Different types of inhibitors generate different transcriptional responses in EGFR-targeted cells \[[@CR9]\].

Unfortunately, after a period, tumors inexorably develop resistance to inhibitors by e.g., overexpression of EGFR ligand, activating mutations in the tyrosine kinase or the ligand-binding domain, or by mutations in downstream or parallel signaling pathways, e.g., Axl or IGFIR \[[@CR10]-[@CR14]\]. Multiple studies focused on defining the secondary mutations that cause resistance to EGFR inhibitors \[[@CR13]-[@CR15]\]. However, much less attention has been paid to the transcriptional and metabolic changes that distinguish the resistant cells from the sensitive ones \[[@CR12]\]. Therefore, we decided to explore the fundamental functional changes that distinguish the resistant cells from the sensitive ones, using transcriptional profiling. To cast a wide net, we used metaanalysis approach to find the differential gene expression between matched pairs of cell lines sensitive and resistant to EGFR inhibitors. Here we included eight studies with 15 distinct datasets directly comparing the transcriptional profiles in EGFR inhibitor-sensitive *vs.* resistant cell lines. The cell lines included non-small cell lung cancer, head and neck cancer, and epidermoid carcinoma cell lines. The inhibitors included both reversible and irreversible kinase inhibitors, as well as antibodies.

We found that in EGFR inhibitor-sensitive cell lines characteristically overexpressed gene ontologies are adhesion, negative regulation of cell proliferation, lipid metabolism and oncogenic processes involving ErbB receptors. But when cells become resistant, ontological categories associated with energy metabolism, immunity involving overexpressing inflammatory cytokines, responses to external and internal stimuli, proliferation and ErbB-independent oncogenic pathways are overexpressed. The specific resistance to Gefitinib apparently develops by overexpressing immunomodulatory genes; resistance to Erlotinib by energy producing mitochondrial pathways; resistance to irreversible inhibitors by overexpressing EGFR ligands, whereas resistance to antibody inhibitors develops differently from the resistance to tyrosine kinase inhibitors.

Methods {#Sec2}
=======

Downloading the data files {#Sec3}
--------------------------

The overall flowchart of our methodology is graphically represented in Additional file [1](#MOESM1){ref-type="media"}: Figure S1.

Different microarray platforms used for transcriptional profiling produced different, characteristic data files, which were worked up separately and then synchronized. The CEL or TXT files deposited in these studies were first downloaded and unzipped. For each study, data obtained from sensitive and resistant cell lines were saved in different columns of excel spread sheets. Datasets obtained from Affymetrix studies were combined and analyzed using RMAExpress for quality control \[[@CR16],[@CR17]\]. For non-Affymetrix studies, where we could not run RMAExpress quality control, we downloaded already normalized, \_RAW.tar files and used these without further modifications, as submitted by the original authors.

Grouping studies for analysis using RankProd software {#Sec4}
-----------------------------------------------------

RankProd package analyses gene expression microarray data specifically to identify differentially expressed genes. RankProd uses non-parametric rank product method to detect genes that are consistently found among the most strongly upregulated ones and the most strongly downregulated ones in a number of replicate experiments, comparing two different condition \[[@CR18]\]. We have combined into a single spreadsheet microarray data for sensitive and resistant cell lines with 20552 common genes in all datasets using data-loader \[[@CR17]\]. Five datasets comprising 214 microarrays and 28235 genes for Gefitinib-sensitive and resistant cell lines were combined into a single excel spreadsheet and analyzed using RankProd. Differentially expressed genes in each of the class were recorded. Microarray data for the seven datasets comprising forty Erlotinib-sensitive and resistant microarrays, having 32062 common genes were combined for analysis using RankProd software \[[@CR17]\].

We have pooled and compared the microarray data for EGFR irreversible inhibitors from two datasets, fourteen microarrays and 21631 common genes. For studying EGFR antibody inhibitors responses we found a single study with 3 microarrays from Cetuximab-sensitive and 3 from resistant cell lines, with 48607 genes.

We used the RankProd Software to find out the genes differentially expressed in EGFR inhibitor-sensitive and resistant cell lines with p-values better than 10^−4^. For each analysis we derived two tables, one representing the ontological categories over expressed in sensitive cell lines and second table with gene ontologies overregulated in resistant cell lines \[[@CR18]\]. The results of the RankProd analysis are presented in Additional file [2](#MOESM2){ref-type="media"}: Figure S2.

DAVID analysis {#Sec5}
--------------

We used online Database for Annotation, Visualization and Integrated Discovery (DAVID) software as described before \[[@CR17],[@CR19]\]. We also generated clusters, which reduced overlaps and redundancies in regulated ontological categories, for Erlotinib-, irreversible inhibitor- and Cetuximab-sensitive and resistant cell lines. These are provided in Additional files [3](#MOESM3){ref-type="media"},[4](#MOESM4){ref-type="media"},[5](#MOESM5){ref-type="media"},[6](#MOESM6){ref-type="media"},[7](#MOESM7){ref-type="media"}, and [8](#MOESM8){ref-type="media"}.

Results {#Sec6}
=======

Datasets characterization {#Sec7}
-------------------------

Inhibitors have been studied principally to find out their mechanism of action in different cancer types. We here aim to study the differential gene expression in EGFR inhibitor-sensitive *vs.* resistant cancer cell lines. We searched GEO Datasets using key term "EGFR Resistance" and, limiting our choices to human cell lines, selected studies that directly compare transcriptional profiles of matched EGFR inhibitor-sensitive *vs.* resistant datasets (Table [1](#Tab1){ref-type="table"}). We found 8 appropriate studies comprising 15 datasets and 274 microarrays. In seven datasets EGFR inhibitor-sensitive *vs.* resistant cell lines were compared without any other treatment. In one study comprising four datasets (GSE38310), two different types of Erlotinib-resistant cell lines were originated from Erlotinib-sensitive cell lines and then treated either with DMSO or Erlotinib. We compared DMSO-treated sensitive cell lines with DMSO-treated resistant cell lines and Erlotinib-treated sensitive cell lines with Erlotinib-treated resistant cell lines. In a Gefitinib study comprising three datasets \[[@CR10]\], sensitive and resistant cell lines were treated with Gefitinib and EGF separately or in combination (GSE34228). In one study Erlotinib-sensitive and resistant cell lines were treated with miR-7 (GSE40130). In another study, GSE38404, resistant cell lines were produced by exposing the sensitive cell lines to inhibitor for different time periods. We have combined data from all the resistant cell lines for metaanalysis.Table 1**EGFR inhibitors-sensitive versus resistant cell lines datasets used in metaanalysis of microarrays**Sr. NoAcc. No.PlatformSetS+RS cell linesR Cell linesCell TypePretreatmentInhibitor1GSE34228Agilent-014850126+26PC9PC9GRNon-Small Cell Lung CancerNoGefitinib226+26PC9PC9GRNon-Small Cell Lung CancerEGFGefitinib326+26PC9PC9GRNon-Small Cell Lung CancerIRSGefitinib426+26PC9PC9GRNon-Small Cell Lung CancerEGF+IRSGefitinib2GSE10696Affy HG\_ U133_Plus_2.013+3A431A431GRA431 cancer cell lineNoGefitinib3GSE38310Illumina HumanHT-12 V3.013+3HCC827T15-2Non-Small Cell Lung CancerDMSOErlotinib23+3HCC827T15-3Non-Small Cell Lung CancerErlotinibErlotinib33+3HCC827ER-3Non-Small Cell Lung CancerDMSOErlotinib43+3HCC827ER-3Non-Small Cell Lung CancerErlotinibErlotinib4GSE40130Illumina HumanWG-6 v3.012+3HN5FADUHead and Neck cancer cell linesNoErlotinibIllumina HumanHT-12 V4.022+3HN5FADUHead and Neck cancer cell linesmiR-7Erlotinib5GSE49135Illumina HumanHT-12 V4.013+3HN5HN5ERHead and Neck cancer cell linesNoErlotinib6GSE37699Affy_HG_U133A_213+3NSCLCNCl-H1975Non-Small Cell Lung CancerNoWZ40027GSE38404Affy_HG_U133A_212+6NSCLCPFR31, PFR32Non-Small Cell Lung CancerNoPF2998048GSE21483Affy HG\_ U133_Plus_2.013+3SCC11Cc8Skin cancer cell lineNoCetuximabTotal15274

Illumina microarrays were used in majority of datasets, comprising 3 studies and 7 datasets. In four studies, comparing four datasets Affymetrix microarrays were used. Agilent microarrays were used in one study comparing four datasets. Different studies used different types of cell lines for example Non-Small Cell Lung Cancer, Head and Neck Cancer, A431 and Skin cancer cell lines; therefore, we have also individually compared datasets from individual studies (data not shown).

Information about the type of sensitive and resistant cells, pretreatment and type of EGFR inhibitor, labeling accession number, platform, number of datasets, number of sensitive and resistant microarray chips in each dataset is summarized in Table [1](#Tab1){ref-type="table"}.

We have compared these datasets using different approaches; 1) datasets comparing all EGFR inhibitor-sensitive *vs.* resistant cell lines; 2) Gefitinib- and 3) Erlotinib-sensitive *vs.* resistant cell lines; 4) irreversible inhibitor-sensitive *vs.* resistant cell lines; 5) Cetuximab-sensitive *vs.* resistant cell lines \[[@CR11]\]. We used RankProd software to select differentially expressed genes in these individual groups i.e. sensitive *vs.* resistant, with results graphically presented in (Additional file [2](#MOESM2){ref-type="media"}: Figure S2).

Ontological categories overrepresented in lists of differentially expressed genes were identified using DAVID \[[@CR19]\]; complete lists are given in Additional files [3](#MOESM3){ref-type="media"}, [4](#MOESM4){ref-type="media"}, [5](#MOESM5){ref-type="media"}, [6](#MOESM6){ref-type="media"} and [7](#MOESM7){ref-type="media"}. To condense redundancies, we have also identified clusters for differentially expressed ontological categories in the sensitive *vs.* Erlotinib-, Irreversible- and Cetuximab-resistant groups (see below).

Global comparison of all EGFR inhibitors-sensitive *vs.* resistant cell lines {#Sec8}
-----------------------------------------------------------------------------

We have compared overexpressed ontological categories in all sensitive *vs*. resistant cell lines. Table [2](#Tab2){ref-type="table"}a contains the 10 categories with the best p-values; in Table [2](#Tab2){ref-type="table"}b, we selected the characteristically different categories between sensitive and resistant cells with p-values better than 10^−4^.Table 2**Global comparison of the ontological categories differentially expressed in EGFR inhibitors-sensitive** ***vs.*** **resistant cell lines**All studies: Overexpressed in sensitive cellsOverexpressed in resistant cellsTermp-valueTermp-value**Table 2aO**Pathways in cancer4.9E-15**T**positive regulation of biosynthetic process3.6E-17**MM**plasma membrane part7.7E-12**T**positive regulation of cellular biosynthetic process5.2E-17**CC**regulation of cell proliferation1.3E-10**T**positive regulation of macromolecule Metabolic process2.3E-16**MM**endomembrane system1.4E-10**R**response to endogenous stimulus8.9E-16**MM**cell fraction2.1E-09**T**positive regulation of nitrogen compound Metabolic process1.6E-15**A**regulation of cell death2.2E-09**T**positive regulation of macromolecule biosynthetic process9.3E-15**A**regulation of programmed cell death2.6E-09**CC**regulation of cell proliferation4.9E-14**Mt**positive regulation of macromolecule Metabolic process2.6E-09**R**response to hormone stimulus6.9E-14**CC**cell proliferation5.7E-09**R**response to organic substance9.6E-14**T**protein complex biogenesis7.0E-09**CC**positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid Metabolic process1.2E-13**Table 2bA**negative regulation of cell death1.4E-07**A**regulation of apoptosis3.3E-10**AD**cell migration5.0E-08**A**negative regulation of apoptosis4.1E-10**AD**cell adhesion2.3E-07**A**anti-apoptosis8.1E-08**AD**localization of cell1.2E-06**CC**cell cycle8.2E-06**AD**cell projection3.2E-06**CC**regulation of cell size3.4E-05**AD**Focal adhesion4.3E-05**CY**cytoskeletal protein binding3.2E-06**CC**negative regulation of cell proliferation9.0E-05**CY**actin cytoskeleton1.0E-04**CC**regulation of DNA Metabolic process1.5E-04**DF**negative regulation of cell differentiation6.1E-06**CC**mitotic cell cycle5.9E-04**E**regulation of oxidoreductase activity5.1E-05**CC**regulation of cell size6.4E-04**E**positive regulation of oxidoreductase activity4.2E-04**IM**response to wounding4.4E-05**IM**immune system development1.8E-09**IM**immune system development6.2E-04**IM**response to wounding2.4E-08**IM**T cell activation6.8E-04**IM**regulation of cytokine production1.1E-07**IM**humoral immune response8.4E-04**IM**positive regulation of immune system process4.3E-06**M_c**oligosaccharide Metabolic process7.0E-04**IM**positive regulation of cell activation2.6E-05**M_l**regulation of lipid Metabolic process6.8E-06**IM**inflammatory response2.8E-05**M_l**phosphoinositide Metabolic process7.3E-05**IM**wound healing1.6E-04**M_l**positive regulation of lipid Metabolic process1.0E-04**IM**immune response1.8E-04**M_l**lipid biosynthetic process1.1E-04**IM**defense response4.5E-04**M_l**phospholipid Metabolic process2.3E-04**IM**regulation of production of molecular mediator of immune response9.1E-04**M_l**cellular lipid catabolic process4.2E-04**M_c**monosaccharide Metabolic process4.3E-06**M_l**glycerolipid Metabolic process5.4E-04**M_c**hexose Metabolic process1.2E-05**M_l**glycerophospholipid Metabolic process7.0E-04**M_c**glucose Metabolic process5.8E-05**M_l**lipoprotein particle clearance9.2E-04**M_c**regulation of cellular ketone Metabolic process2.0E-04**O**Oncogenesis3.4E-05**M_l**regulation of lipid Metabolic process2.6E-07**O**ErbB signaling pathway4.2E-04**M_l**regulation of lipid biosynthetic process1.1E-04**O**Wnt signaling pathway7.7E-04**M_l**regulation of fatty acid Metabolic process4.2E-04**M_l**positive regulation of lipid Metabolic process4.9E-04**Legend:MO**regulation of cell motion2.8E-12**A**Apoptosis**O**Pathways in cancer2.8E-10**AD**Adhesion**O**regulation of DNA Metabolic process1.2E-04**CC**Cell cycle**O**Ras protein signal transduction2.1E-04**CY**Cytoskeleton**O**Oncogenesis4.0E-04**DF**Differentiation**R**response to steroid hormone stimulus6.2E-12**E**Energy**R**response to insulin stimulus1.5E-07**Mt**Metabolism**R**response to vitamin1.2E-06**IM**Immunity**R**response to lipopolysaccharide1.8E-06**M_c**Metabolism-carbohydrates**R**response to glucocorticoid stimulus2.6E-06**M_l**Metabolism-lipids**R**response to hydrogen peroxide1.4E-05**MM**Membrane**R**cellular response to stress3.1E-05**MO**Motility**V**regulation of angiogenesis4.6E-06**O**Oncogenesis**V**myeloid leukocyte activation4.4E-05**R**Response to stimuli**V**positive regulation of angiogenesis4.2E-04**T**Transcription/translation**V**Vasculogenesis**SensitiveResistantTable 2cErbB Signalling pathwayRas protein signal transduction**BCL2-associated agonist of cell deathv-ral oncogene homolog Amitogen-activated protein kinase 9FERM, RhoGEF and pleckstrin domainphosphoinositide-3-kinase betanischaringlycogen synthase kinase 3 betaIGF1 (somatomedin C)c-abl oncogene 1Rho GTPase activating protein 6v-crk sarcoma virus CT10X-associated ankyrin-containing proteinmitogen-activated protein kinase 8ras homolog gene family, member Aribosomal protein S6 kinasemyosin IXBmitogen-activated protein kinase 10mitogen-activated protein kinase 1phosphoinositide-3-kinase alphaGRB2-related adaptor protein 2phospholipase C, gamma 1Rho GTPase activating protein 5CDK inhibitor 1A (p21, Cip1)soc-2 suppressor of clear homologepiregulinmitogen-activated protein kinase 14v-myc oncogene homologropporin, rhophilin associated protein 1Bphosphoinositide-3-kinase subunit 5r-ras oncogene homologv-erb-b2 oncogene homolog 2CDC42 effector proteinv-aktoncogene homolog 1fibroblast growth factor 2 (basic)calcium/calmodulin-dep. protein kinase IIG protein alpha 12protein kinase C, alphaparathyroid hormoneneuregulin 1GRB2-related adaptor proteinNCK adaptor protein 1muscle RAS oncogene homologPTK2 protein tyrosine kinase 2WAS protein family, member 2phosphoinositide-3-kinase deltaSHC transforming protein 1betacellulinMAPKAP 2ribosomal protein S6 kinase 2Rho guanine nucleotide exchange factor 3jun oncogeneATP-binding cassette, member 1p21 (Cdc42/Rac)-activated kinase 2cofilin 1 (non-muscle)translation initiation factor 4E bindingCDC42 effector protein 4phospholipase C, gamma 2neurofibromin 1neurotrophic tyrosine kinase, type 1ral GDF stimulator-like 2linker for activation of T cells**SensitiveResistantTable 2dComplement System**complement component 2complement component 1, q A chaincomplement component 3a receptor 1complement component 1, q B chaincomplement component 7complement factor Hcomplement component 8, alphacomplement component 8, betacomplement component 9complement factor Bcomplement factor Hcomplement factor I**Chemokines**chemokine (C-C motif) ligand 2chemokine (C-C motif) ligand 13chemokine (C-C motif) ligand 22chemokine (C-C motif) ligand 19chemokine (C-C motif) ligand 23chemokine (C-C motif) ligand 2chemokine (C-C motif) ligand 24chemokine (C-C motif) ligand 20chemokine (C-C motif) receptor 5chemokine (C-C motif) ligand 8chemokine (C-C motif) receptor 5chemokine (C-X-C motif) ligand 1chemokine (C-X-C motif) ligand 13chemokine (C-X-C motif) ligand 6**Interleukins**interleukin 1, alphainterleukin 1 family, member 6interleukin 10interleukin 1, alphainterleukin 2 receptor, alphainterleukin 1, betainterleukin 6 (interferon, beta 2)interleukin 10interleukin 8interleukin 10 receptor, betainterleukin 13interleukin 22interleukin 5interleukin 6 (interferon, beta 2)interleukin 9The data represent the ontological and functional categories identified as overrepresented in the lists of differentially expressed genes, when compared to all genes in the human genome. The lists are provided by the DAVID analysis program \[[@CR17],[@CR19]\]. a) Top ten categories with best p-values. b) Selected categories with p-value better than 10^-4^. For complete list of categories with p-values better than 10^-4^ see Additional file [3](#MOESM3){ref-type="media"}; the selected categories represent our choices as the ones that illustrate the best differences between resistant and sensitive cell lines. c) Genes expressed in ErbB signaling pathway and Ras protein signal transduction ontologies of sensitive and resistant cell lines respectively. d) Genes expressed in immune system development of sensitive versus resistant cell lines.

In Table [2](#Tab2){ref-type="table"}a, we find that in the sensitive cell lines the genes related to systems involved in transport of materials across the membranes are overexpressed, whereas in the resistant cell lines the genes related to the metabolism and macromolecule biosynthesis, especially of proteins, are overexpressed. Although we have found genes associated with regulation of the protein translation in both groups, this category is more significant in the resistant cell lines. Both EGFR inhibitor-sensitive and resistant cell lines overexpress cell proliferation genes, however the sensitive cell lines tend to overexpress apoptosis and cancer-related genes as well. Interestingly, the resistant cell lines seem significantly more responsive to various endogenous and exogenous stimuli than the sensitive ones.

Oncogenesis-related genes and pathways are up-regulated in both sensitive and resistant cell lines. As reported in previous studies, in sensitive cell lines tumor growth seems dependent on the oncogene activation through ErbB receptor kinases \[[@CR15]\]. In contrast, in resistant cell lines often the Ras pathway is activated independently of receptors (Table [2](#Tab2){ref-type="table"}b). We note that while Ras is considered a downstream target of EGFR signaling in noncancerous cells \[[@CR20]\], the EGFR- and Ras-associated genes comprise widely different groups (Table [2](#Tab2){ref-type="table"}c).

Interestingly, we have observed that in the sensitive cell lines lipids are preferentially metabolized as the source of energy. But as cells become resistant, both carbohydrates and lipids are metabolized to provide energy. In addition, resistant cell lines are inducing the expression of energy generating genes, including the oxidoreductases. This observation suggests that energy production is an important matter for development of resistant cell lines.

Genes involved in responses to various extracellular and intracellular stimuli, for example steroid hormone, hydrogen peroxide and stress, are over expressed significantly in the resistant cell lines compared to sensitive ones. These responses may be related either to cells' protection from toxins or overall cell survival, as stress and hydrogen peroxide responses prepare the cell for a toxic environment and steroids stimulate proliferation in certain cancers \[[@CR21],[@CR22]\]. Those cancer cells that increase expression of genes responsive to these stimuli tend to adapt and survive \[[@CR23]\].

We have also observed that certain processes related to immunity are overexpressed in the sensitive as well as in resistant cell lines, but we found that ontological categories for these processes have significantly better p-values in the resistant ones. Further, detailed study of the genes involved in immunity revealed that the innate immunity involving the complement component system is active in sensitive cells. In contrast, the resistant cells utilize both innate and adaptive immune systems, especially involving the cytokines and chemokines (Table [2](#Tab2){ref-type="table"}d).

In EGFR inhibitor-sensitive cell lines, cell death and proliferation are relatively suppressed. But in resistant cell lines proliferation is relatively increased, while differentiation is decreased, thus favoring cancer cells growth and persistence. Another major distinction is that sensitive cell lines strongly express adhesion-related genes, whereas in resistant cells the genes related to cell movement are overexpressed. This suggests that the resistant cells have increased tendency to metastasize, perhaps *via* EMT \[[@CR13],[@CR24]\].

Comparison of Erlotinib-sensitive *vs.* resistant cell lines {#Sec9}
------------------------------------------------------------

Surprisingly, protein biosynthesis was the only ontological category in the top ten differentially expressed ones in Erlotinib-sensitive cell lines (Table [3](#Tab3){ref-type="table"}a). In the resistant cells, we have also found mitochondria, immunity and cytoskeleton genes in the top ten ontological categories. In Erlotinib-sensitive cell lines, carbohydrate and protein metabolism genes are overexpressed with very good p-values, 10^−21^ (Table [3](#Tab3){ref-type="table"}b). These lines seem to utilize the maximum of their energy reservoirs from glucose and protein molecules. Conversely, in the Erlotinib-resistant cell lines, glycolysis and gluconeogenesis are suppressed and, importantly, genes related to mitochondria and mitochondrial processes are remarkably boosted. These results suggest that increased production of energy to support cellular metabolic processes and survival are very important in the development of Erlotinib resistance. From these observations we suggest that energy level could be the limiting factor for the tumor cells survival in the presence of EGFR inhibitors.Table 3**Comparison of ontological categories differentially expressed in Erlotinib-sensitive** ***vs.*** **resistant cell lines, using DAVID program**Erlotinib: Overexpressed in sensitive cellsOverexpressed in resistant cellsTermp_valueTermp_value**Table 3aT**translation5.6E-62cytosol3.0E-20**T**translational elongation6.3E-45**T**translational elongation3.1E-18**T**structural constituent of ribosome1.0E-43**T**structural constituent of ribosome3.4E-18cytosol3.7E-41**T**ribosomal subunit3.5E-17**T**ribosome4.5E-41**T**cytosolic ribosome2.4E-16**T**3\' -UTR-mediated translational regulation3.8E-40**E**mitochondrion1.5E-15**T**ribonucleoprotein complex5.0E-40**T**Ribosome2.6E-14**T**Ribosome4.6E-37**T**ribosome2.6E-14**T**ribosomal subunit9.9E-36**IM**Influenza Infection4.2E-14**T**Protein biosynthesis2.0E-33**CY**intracellular non-membrane-bounded organelle8.2E-13**Table 3bCC**Cell cycle1.8E-04**CC**mitotic cell cycle3.2E-08**E**mitochondrion2.4E-10**CC**M phase of mitotic cell cycle9.1E-06**E**intramolecular oxidoreductase activity4.4E-04**CY**actin cytoskeleton5.3E-06**M_c**glycolysis2.1E-07**E**mitochondrial inner membrane7.1E-12**M_c**Metabolism of carbohydrates3.3E-06**E**mitochondrial envelope7.2E-12**M_c**carbohydrate catabolic process7.5E-05**E**oxidative phosphorylation1.5E-10**M_c**Glycolysis / Gluconeogenesis1.7E-04**E**hydrogen ion transmembrane transporter activity1.8E-10**M_c**glucose metabolic process6.4E-04**E**generation of precursor metabolites and energy3.4E-10**T**Metabolism of proteins5.4E-29**E**Oxidoreductase6.6E-10**T**ribosome biogenesis6.6E-21**E**Dehydrogenase3.9E-09**T**ncRNA metabolic process4.7E-19**E**Integration of energy metabolism1.6E-06**T**mitochondrial ribosome4.0E-05**E**electron transport chain1.8E-05**E**mitochondrial lumen1.9E-04**E**mitochondrial matrix1.9E-04**E**NADH dehydrogenase (ubiquinone) activity2.3E-04**E**mitochondrial ATP synthesis coupled electron transport2.8E-04**T**Metabolism of proteins2.7E-09**T**Protein biosynthesis1.6E-07**T**Gene Expression1.5E-06a) Top ten categories with best p-values. b) Selected categories with p-value better than 10^-4^ (see Additional file [4](#MOESM4){ref-type="media"}).

Comparison of Gefitinib-sensitive *vs.* resistant cell lines {#Sec10}
------------------------------------------------------------

In the Table [4](#Tab4){ref-type="table"}a, we show that the cancer-related genes and pathways are preferentially activated in the sensitive cell lines. But in the cells resistant to Gefitinib, the ontological categories related to macromolecule biosynthesis, specifically of proteins, are most significantly overexpressed. Apparently, the sensitive cell lines have higher tendency for attachment, as the adhesion related genes are upregulated in these, whereas the resistant cell lines are significantly more responsive to endogenous and exogenous stimuli. In the sensitive cell lines ontological categories related to cell cycle, metabolism of proteins and signaling are also up regulated, but the p-values are not as significant as in the resistant cell lines. Tumor related pathways and cell cycle-related genes are also relatively upregulated in resistant cell lines.Table 4**Comparison of ontological categories differentially expressed in Gefitinib-sensitive** ***vs*** **. resistant cell lines**Gefitinib: Overexpressed in sensitive cellsOverexpressed in resistant cellsTermp_valueTermp_value**Table 4aO**Pathways in cancer6.8E-14**T**positive regulation of biosynthetic process1.7E-11**O**Pancreatic cancer1.2E-07**T**positive regulation of macromolecule metabolic process3.1E-11**T**protein complex assembly3.7E-06**T**positive regulation of cellular biosynthetic process3.5E-11**T**protein complex biogenesis3.7E-06**T**positive regulation of nitrogen compound metabolic process1.6E-10**CC**regulation of cell proliferation3.9E-06**T**positive regulation of macromolecule biosynthetic process4.4E-10**O**Bladder cancer7.8E-06**R**response to endogenous stimulus5.1E-10**S**regulation of protein kinase cascade8.7E-06**CC**positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process3.6E-09**AD**cell adhesion9.0E-06**R**response to hormone stimulus8.1E-09**AD**biological adhesion9.8E-06**O**Pathways in cancer1.0E-08**T**positive regulation of macromolecule metabolic process1.0E-05**T**positive regulation of transcription1.5E-08**Table 4bA**regulation of cell death3.6E-05**A**negative regulation of programmed cell death1.0E-06**A**negative regulation of cell death4.4E-05**CC**regulation of cell proliferation3.5E-08**A**regulation of apoptosis7.9E-05**CC**positive regulation of cell proliferation1.9E-06**CC**cell proliferation1.6E-05**CC**cell cycle2.7E-04**M_l**regulation of lipid metabolic process3.1E-05**CY**cytoskeleton organization5.3E-06**M_l**positive regulation of lipid metabolic process3.4E-04**CY**cell morphogenesis2.0E-04**O**ErbB signaling pathway5.2E-04**E**regulation of oxidoreductase activity4.9E-04**HY**response to hypoxia8.7E-06**HY**response to reactive oxygen species2.4E-04**HY**response to hydrogen peroxide6.3E-04**IM**immune system development4.1E-07**IM**regulation of cytokine production9.2E-07**IM**regulation of cytokine biosynthetic process2.8E-06**IM**response to wounding7.3E-05**IM**positive regulation of cytokine biosynthetic process1.1E-04**IM**Signaling in Immune system1.3E-04**M_c**glucose metabolic process5.1E-04**M_l**regulation of lipid metabolic process2.9E-04**R**response to steroid hormone stimulus4.5E-08**R**response to nutrient levels3.6E-07**R**response to extracellular stimulus6.8E-07**R**response to drug2.5E-06**R**response to nutrient3.7E-05**R**response to vitamin3.7E-05**R**response to corticosteroid stimulus4.3E-05**R**response to glucocorticoid stimulus9.1E-05**R**response to lipopolysaccharide1.7E-04**R**response to abiotic stimulus3.4E-04**R**negative regulation of response to external stimulus6.8E-04**V**hemopoiesis1.2E-07**V**leukocyte differentiation9.4E-06**V**blood circulation4.9E-05**V**circulatory system process4.9E-05**V**lymphocyte differentiation7.4E-05**V**regulation of angiogenesis1.1E-04**V**blood vessel development1.2E-04**V**vasculature development1.8E-04a) Top ten categories with best p-values. b) Selected categories with p-value better than 10^-4^ (see Additional file [5](#MOESM5){ref-type="media"}).

Interestingly, we have not found any ontological category related to immune system development overexpressed in the sensitive cell lines. In contrast, in the resistant cell lines immunity systems, specifically biosynthesis of cytokines genes, are boosted (Table [4](#Tab4){ref-type="table"}b). This suggests that Gefitinib-resistant cell lines use cytokines of the immune systems to develop resistance against Gefitinib and thus maintain tumor cells growth and progression \[[@CR25]\].

In resistant cells the ontological categories related to responses to various stimuli and angiogenesis were robustly and consistently overexpressed. We have also found increased expression of genes responsive to reactive oxygen species, which ultimately tends to activate apoptosis and immunity pathways in these cells. Expression of genes related to hypoxia has also been seen in the resistant cell lines, which may increase their drug resistance and ultimately their growth rate \[[@CR26]\].

Both in Gefitinib-sensitive and in resistant cell lines proliferation and apoptosis are regulated. However, in the resistant cell lines, the cell death processes are negatively regulated and the cell division is enhanced, suggesting that resistant cell lines have higher propensity to survive. Meanwhile, responses to various endogenous and exogenous stimuli are enhanced, maybe to cope with stresses from environment. In addition, immunity genes and cytokine biosynthesis are upregulated to help cancer cells to survive and grow.

Interestingly, we have observed that lipid metabolism genes are prominent in the sensitive cell lines, whereas oxidoreductases, as well as both glucose and lipid metabolism, i.e. genes related to production of energy, are more prominent in the resistant cell lines. Energy requirements for the tumor cells are met preferentially by formation of new blood vessels but also by glucose and lipid metabolism.

Comparison of sensitive *vs.* resistant cell lines obtained using irreversible EGFR inhibitors {#Sec11}
----------------------------------------------------------------------------------------------

We have combined the microarray data from the cell lines selected as resistant to irreversible EGFR inhibitors WZ4002 and PF299804. Unexpectedly, in the top ten categories from the sensitive cell lines, genes related to membrane systems are found (Table [5](#Tab5){ref-type="table"}a). In contrast, the extracellular region-related ontological categories are upregulated in the resistant cell lines. Cell cycle and lipid metabolism categories are relatively upregulated in the sensitive cell lines, similar to what was observed in reversible EGFR inhibitors-sensitive cell lines (Table [4](#Tab4){ref-type="table"}b). Ontological categories related to cell division were found in both groups, however, in the resistant cell lines, cell division is positively regulated with better p-value than in sensitive cell lines. Importantly, the immunity genes are relatively overexpressed in resistant cell lines, reinforcing our observation that cytokine overexpression is one of the survival strategies gained by resistant cell lines (Table [5](#Tab5){ref-type="table"}b).Table 5**Comparison of ontological categories differentially expressed in irreversible inhibitor-sensitive** ***vs*** **. resistant cell lines**Irreversible: Overexpression in sensitive cellsOverexpression in resistant cellsTermp_valueTermp_value**Table 5aMM**endomembrane system3.8E-09**EC**extracellular region1.6E-08**MM**Golgi apparatus2.4E-07ectoderm development3.3E-07**MM**cell fraction1.0E-05**IM**response to wounding4.3E-07**CC**cell division2.1E-05**EC**extracellular region part1.3E-06**MM**organelle membrane3.1E-05**EC**extracellular space2.4E-06**MM**nuclear envelope-endoplasmic reticulum network5.9E-05epidermis development8.4E-06**R**response to organic substance8.1E-05**CC**regulation of cell proliferation1.1E-05**MM**endoplasmic reticulum membrane1.0E-04**CC**regulation of smooth muscle cell proliferation6.5E-05**CC**Mitosis1.1E-04**IM**wound healing7.3E-05**MM**1p22.11.5E-04**CC**positive regulation of smooth muscle cell proliferation1.9E-04**Table 5bCC**cell cycle3.1E-04**IM**defense response5.9E-04**M_l**steroid metabolic process4.3E-04**IM**inflammatory response9.2E-04**O**epidermal growth factor receptor binding2.5E-04**O**ErbB signaling pathway4.2E-04**Genes overexpressed in resistant cellsTable 5cEGFR Binding ligandsErbB sig pathway**amphiregulin; amphiregulin BCas-Br-M ecotropic retroviral transforming sequence cepidermal growth factor receptoramphiregulin; amphiregulin BEpiregulinepidermal growth factor receptorheparin-binding EGF-like growth factorepiregulinheparin-binding EGF-like growth factortransforming growth factor, alphav-erb-b2 oncogene homolog 3a) Top ten categories with best p-values. b) Selected categories with p-value better than 10^-4^ (see Additional file [6](#MOESM6){ref-type="media"}). c) Genes expressed in EGFR binding and ErbB signaling pathway ontologies in resistant cell lines.

Surprisingly, we found increased expression of EGFR ligands in cells selected using irreversible inhibitors (Table [5](#Tab5){ref-type="table"}b). Perhaps these cells are still dependent on EGFR-mediated signaling cascades. This differs from observations in cell lines selected for resistance to reversible inhibitors, which use alternative pathways for oncogenes activation (Tables [2](#Tab2){ref-type="table"}b and [3](#Tab3){ref-type="table"}b).

Comparison of Cetuximab-sensitive *vs.* resistant cell lines {#Sec12}
------------------------------------------------------------

For the analysis of cells selected as resistant to antibody inhibitor Cetuximab, we could find only a single study including six microarrays \[[@CR27]\], which means that the statistical robustness of the results is reduced. Interestingly, we found that the differential gene expression in Cetuximab-sensitive and resistant cell lines is quite unlike the differential gene expression seen in the cell lines obtained using tyrosine kinase inhibitors. This agrees well with our previous study documenting that the transcriptional responses to EGFR antibody inhibitors are different from those to kinase inhibitors \[[@CR9]\]. In sensitive cell lines, ontological categories related to immunity, cell proliferation, cell migration and response to external stimulus are overexpressed (Table [6](#Tab6){ref-type="table"}a). In contrast, in the resistant cell lines epithelium development- and differentiation-associated gene ontologies are frequently and significantly overexpressed. Intriguing, the ontological category for wound response was overexpressed in resistant cells as well, although it had relatively less significant p-value.Table 6**Comparison of ontological categories differentially expressed in Cetuximab-sensitive** ***vs*** **. resistant cell lines**Cetuximab: Overexpressed in sensitive cellsOverexpressed in resistant cellsTermp_valueTermp_value**Table 6aIM**response to wounding1.3E-10**DF**ectoderm development9.2E-10**CC**regulation of cell proliferation1.6E-09**DF**epidermis development1.4E-09**CC**positive regulation of cell proliferation3.5E-07**DF**epithelium development1.0E-08**M**chemotaxis8.9E-07**DF**epithelial cell differentiation1.5E-07**M**taxis8.9E-07**DF**keratinocyte differentiation6.2E-05**M**cell migration1.7E-06**DF**cornified envelope6.5E-05**M**localization of cell2.6E-06**EC**extracellular matrix7.8E-05**M**cell motility2.6E-06**DF**epidermal cell differentiation1.2E-04**M**Cell communication3.5E-06**DF**peptide cross-linking1.7E-04**R**regulation of response to external stimulus4.0E-06**IM**wound healing1.7E-04**Table 6bIM**inflammatory response6.5E-06**CC**regulation of cell proliferation4.3E-04**IM**wound healing9.1E-06**CY**Cell structure and motility3.3E-04**IM**immune response9.8E-06**CY**12q12-q136.9E-04**IM**Immunity and defense6.7E-05**T**transcription repressor activity8.4E-04**IM**regulation of inflammatory response3.5E-04**S**Signal transduction1.5E-05**S**Jak-STAT signaling pathway5.1E-04**S**JAK-STAT cascade6.7E-04**V**regulation of vascular endothelial growth factor production3.2E-05**V**Angiogenesis3.8E-05**V**blood coagulation5.8E-04a) Top ten categories with best p-values. b) Selected categories with p-value better than 10^-4^ (see Additional file [7](#MOESM7){ref-type="media"}).

In Table [6](#Tab6){ref-type="table"}b, the overregulated processes in Cetuximab-sensitive cell line comprise immunity responses, signal transduction involving JAK-STAT pathway and angiogenesis. In contrast, in the resistant cell line genes for cell cycle, cell structure and reduction of transcription are increased.

Clustering of ontological categories in sensitive *vs.* resistant cell lines {#Sec13}
----------------------------------------------------------------------------

The charts comparing overexpressed ontological categories, although very informative, contain many redundant and overlapping ontological categories (Tables [2](#Tab2){ref-type="table"},[3](#Tab3){ref-type="table"},[4](#Tab4){ref-type="table"},[5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}). To get around this problem we have clustered the ontological categories using DAVID software. Cluster outputs for Erlotinib-, irreversible inhibitor and Cetuximab-sensitive versus resistant cell lines are presented in Additional file [8](#MOESM8){ref-type="media"}.

In Erlotinib-sensitive cell lines, transcription, translation and protein transport processes, marked as 'T' in Additional file [8](#MOESM8){ref-type="media"}a, are statistically more significant. In contrast, we found mitochondria-related genes, designated as 'E' for 'energy', the most frequent ontological category in resistant cell lines. Ontologies related to apoptosis, 'A', are the second most upregulated category in sensitive cells. In resistant cell lines genes related to cell cycle, 'CC', and cytoskeleton, 'CY', are the most expressed categories after energy production. In sensitive cell lines apparently energy is spent for synthesizing proteins and regulating cell death processes, whereas in resistant cells energy is mainly produced and utilized in cell growth maintenance. Thus, if this hypothesis is confirmed by the laboratory approaches, energy starvation strategies could be used to treat cancer cells.

Unexpectedly, categories 'M', describing motion of cells, and 'V', denoting the vascularization and angiogenesis, were found in sensitive cell lines, whereas adhesion-related genes, 'AD', were found relatively overexpressed in resistant cell lines. We have also found that certain categories related to energy metabolism; marked as 'M-c' for metabolism of carbohydrates and 'E' for energy-related processes are also up regulated in sensitive cells (Additional file [8](#MOESM8){ref-type="media"}a).

Although extracellular region 'EC' is the top regulated category in irreversible inhibitor-resistant cell lines, important EGFR-activated cellular processes, including immunity, 'IM', angiogenesis, 'V', and cytoskeleton, 'CY', were upregulated (Additional file [8](#MOESM8){ref-type="media"}b). In sensitive cell lines membrane systems, 'MM', response to hormones, 'R', and cell cycle, 'CC', were upregulated.

In Cetuximab antibody-resistant cell lines, many ontological categories are suppressed. For example, ontological category 'IM', immunity, is statistically the most prominent, biosynthesis of inflammatory cytokine and responses to these cytokines are specifically downregulated. We have observed that gene ontologies related to migration of the cells, marked 'M', are prominent in Additional file [8](#MOESM8){ref-type="media"}c. Cell adhesion categories, designated as 'AD', are also present there but the enrichment score and p-values are comparatively less. Blood vessels development processes, 'V', are overexpressed in Cetuximab-sensitive cell lines.

We have also found increased expression of signaling, 'S', apoptosis inhibition, 'A', and homeostasis-related genes, 'H', in sensitive cell lines, but not in resistant cell lines. Some of the overregulated clusters were also related to cell cycle, 'CC', transcription, 'T', and responses to external stimuli, 'R'. Ectoderm development category was overexpressed with higher p-value in antibody-resistant cell lines, reflecting epidermal cell origin. Other ontological categories were extracellular matrix 'EC' and adhesion (Additional file [8](#MOESM8){ref-type="media"}c).

As observed above, (Tables [3](#Tab3){ref-type="table"},[4](#Tab4){ref-type="table"},[5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}), we have seen that responses of antibody-resistant cell line are reverse of those observed in tyrosine kinase inhibitors-resistant cell lines (comparing Additional files [8](#MOESM8){ref-type="media"}a and b with Table [6](#Tab6){ref-type="table"}c). All ontological categories observed in Cetuximab-sensitive cell lines seem responsible for tumor cell survival and progression and were previously seen overexpressed in tyrosine kinase inhibitor-resistant cell lines.

Discussion {#Sec14}
==========

Global metaanalysis of EGFR inhibitor-resistant *vs.* sensitive cell lines presented here identifies the transcriptional and metabolic differences that allow tumor cells to evade EGFR-targeted therapies. Specifically, we find that the most acute problem created by EGFR inhibition is to provide a sufficient energy supply to the proliferating and metabolizing transformed cells. This metabolic predicament for tumors was one of the first ones identified, already by Warburg in 1927 \[[@CR28]\]. The energy deficit caused by inhibition of EGFR is overcome by several mechanisms, e.g., by major enhancement of the mitochondrial oxidative phosphorylation in Erlotinib-inhibited cells, or by promoting vascularization and angiogenesis in Gefitinib-inhibited tumors.

In aerobic glycolysis, tumor cells produce lactate by glycolysis in the presence of oxygen and decrease the oxidative phosphorylation due to presence of an isoform of pyruvate kinase. If pyruvate kinase is in its native form, then increased oxygen uptake and oxidative phosphorylation occur and lactate formation is decreased \[[@CR29]\]. In metaanalysis of Erlotinib-resistant cells we found that mitochondrial processes involving oxidative phosphorylation were upregulated. Moreover, the resistant cells recruit supplementary energy sources, inducing enzymes that catabolize carbohydrates in addition to those catabolizing lipids.

Additionally, our study proposes that EGFR tyrosine kinase inhibitors-resistant cancer cell lines express specific inflammatory cytokines and angiogenesis signals to promote vascularization and perhaps autocrine immunity stimulation as important strategy to combat cancer treatment \[[@CR13],[@CR30]\]. In-depth perusal of the processes enhanced in the resistant cell lines revealed involvement of interleukins and chemokines with C-X-C motif. These observations are in line with previously known facts that cancer cells use immune cells and cytokines in various ways to maintain their own proliferation \[[@CR25]\]. This mode of overcoming EGFR inhibition is particularly prominent in cells selected for Gefitinib resistance.

Perhaps expectedly, while the sensitive cell lines depend on the ErbB-dependent signaling, resistant ones circumvent this pathway and, at least in some cases, rely on the Ras pathway. Parenthetically, the mutations that confer EGFR inhibitor resistance generally occur in EGFR, seldom in Ras. In targeted therapy, as is case of EGFR inhibition, small molecules targeting tyrosine kinase domain of EGFR or monoclonal antibodies specifically blocking the ligand binding site are used. In some tumors, ErbB-independent signaling is sustained by activation of downstream molecules, for example Ras, *PKI3CA* and *BRAF* \[[@CR15],[@CR21],[@CR31]-[@CR34]\]. Correspondingly, we find that in EGFR inhibitor-resistant cell lines, Ras-dependent oncogenic pathways are preferentially expressed as a strategy to overcome the EGFR inhibition (Table [2](#Tab2){ref-type="table"}b). Detailed analysis of the ErbB and Ras pathway genes enhanced in the sensitive and resistant cell lines respectively, revealed that genes involved in these ontological categories are quite dissimilar (Table [2](#Tab2){ref-type="table"}d).

Interestingly, we found that irreversible inhibitors of the EGFR signaling pathway increased in resistant cell lines the expression of multiple EGFR ligands (Table [5](#Tab5){ref-type="table"}b,c). This seems to be an important alternative to other modes of overcoming EGFR inhibition \[[@CR11],[@CR35]\].

Hypoxia stimulates various processes in cancer cells including vascularization, growth factor signaling, genetic instability, cell survival, metastasis, cell death and antitumor drug resistance, in general favoring tumor survival and propagation \[[@CR36]\]. The cells in surrounding areas of low oxygen are considered resistant to antitumor drugs mainly due to non-availability of drug, change in responses to drug, induction of drug-resistant genes, increase in mutations, angiogenesis and metastasis genes enhancement \[[@CR26]\]. Metaanalysis comparing data from Gefitinib-sensitive versus resistant cell lines revealed that gene ontologies responsive to lower oxygen levels are specifically upregulated in resistant cell lines thus favoring survival. This finding further supports our observation that use of different inhibitors results in different, specific strategies to resist the antitumor targeted therapy.

An important caveat in this analysis stems from the fact that few of the studies, namely GSE34228 and GSE38310 for Gefitinib and Erlotinib, respectively, dominate the metaanalysis by overwhelming numbers of microarrays. Therefore, we cannot claim at this point that it is the resistance to Gefitinib that specifically produces the described changes in all cell lines selected for resistance to Gefitinib, and *mutatis mutandis*, the same for Erlotinib. However, we note that both GSE34228 and GSE38310 compared Non-Small Cell Lung Cancer lines, so the characteristic differences between Gefitinib- *vs*. Erlotinib-selected resistance cannot be ascribed to different cell types. Additional data are needed to corroborate or refute inhibitor-specific characteristics of resistant cells. That said, our previous metaanalysis demonstrated that different inhibitors, although working by ostensibly same mechanisms, cause identifiably different transcriptional responses, which allows for inhibitor-specific developments of resistance as well.

Conclusions {#Sec15}
===========

This metaanalysis of transcriptional and metabolic differences between EGFR inhibitor-resistant *vs.* sensitive cell lines identifies changes that allow tumor cells to evade EGFR-inhibition. The use of different inhibitors results in different, specific strategies to resist the antitumor therapy. Common pathways are upregulated in cell lines resistant to inhibitors targeting the kinase domain of EGFR, however, there are certain processes uniquely expressed against some of the inhibitors but, apparently, not others. The development of resistance to antibody inhibitors can vary significantly.

We found that the most acute problem created by EGFR inhibition is to provide a sufficient energy supply to the cells. The energy deficit can be overcome by several routes, e.g., by boosting mitochondrial oxidative phosphorylation, or by promoting vascularization and angiogenesis.

Further study of sensitive and resistant cancer cell lines responses to additional EGFR inhibitors will improve our understanding of drug resistance development and thus lead to improved anticancer treatment strategies. For example, use of mitochondrial blockers with Erlotinib, immunity blockers with Gefitinib, or combining tyrosine kinase inhibitors with antibody inhibitors, may avoid development of resistance to EGFR inhibitors.

Additional files {#Sec16}
================

Additional file 1: Figure S1.Flow chart of metaanalysis procedure. Additional file 2: Figure S2.Differentially expressed genes in sensitive cell lines *vs.* resistant cell lines. Top panels genes overexpressed in resistant cell lines, bottom panels genes overexpressed in sensitive cell lines. a) All studies. b) Gefitinib. c) Erlotinib. d) Irreversible inhibitors. e) Cetuximab. Additional file 3:**Ontological categories characteristically expressed in EGFR inhibitors-sensitive** ***vs.*** **resistant cell lines.** Additional file 4:**Ontological categories characteristically expressed in Erlotinib-sensitive** ***vs.*** **resistant cell lines.** Additional file 5:**Ontological categories characteristically expressed in Gefitinib-sensitive** ***vs.*** **resistant cell lines.** Additional file 6:**Ontological categories characteristically expressed in irreversible inhibitors-sensitive** ***vs.*** **resistant cell lines.** Additional file 7:**Ontological categories characteristically expressed in Cetuximab-sensitive** ***vs.*** **resistant cell lines.** Additional file 8:**a. Cluster analysis for Erlotinib Sensitive*vs.*regulated analysis using DAVID software.** For complete lists see Additional file [4](#MOESM4){ref-type="media"}. Additional files 8b and 8c Clusters of differentially expressed gene ontologies in irreversible inhibitor- and Cetuximab-sensitive *vs*. resistant cell lines, respectively. For complete lists see Additional files [6](#MOESM6){ref-type="media"} and [7](#MOESM7){ref-type="media"}.
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